Neoprobe Corp. (NASDAQ:NEOP) announced that it has signed alicensing agreement with the University of California, LosAngeles, for a beta-radiation detection probe used duringsurgery to locate cancer.
The beta-detection technology complements Neoprobe'sgamma-detection system for the diagnosis and surgicaltreatment of cancer.
Currently the beta-detection device is being evaluated for thesurgical treatment of neurological tumors in clinical studies atUCLA, Memorial Sloan Kettering Hospital and CreightonUniversity.
Following initial brain tumor clinical evaluation, Neoprobe ofColumbus, Ohio, plans to develop the device to be used inendoscopic and/or laproscopic systems for other solid tumorcancers.
(c) 1997 American Health Consultants. All rights reserved.